![Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/4/11/49102172-15549971542285376_origin.png)
Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha
![VTSMX - Vanguard Total Stock Market Index Fund Investor Shares reports 6.23% increase in ownership of PBYI / Puma Biotechnology Inc. - 13F, 13D, 13G Filings - Fintel.io VTSMX - Vanguard Total Stock Market Index Fund Investor Shares reports 6.23% increase in ownership of PBYI / Puma Biotechnology Inc. - 13F, 13D, 13G Filings - Fintel.io](https://images.fintel.io/us-PBYI-vanguard-index-funds-vanguard-total-stock-market-index-fund-investor-shares.png)
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares reports 6.23% increase in ownership of PBYI / Puma Biotechnology Inc. - 13F, 13D, 13G Filings - Fintel.io
![Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta Win Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta Win](https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2012/cancer-390322_1920_1.jpg)